Daymark Wealth Partners LLC Purchases 23,985 Shares of STERIS plc (NYSE:STE)

Daymark Wealth Partners LLC grew its holdings in STERIS plc (NYSE:STE) by 384.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,222 shares of the medical equipment provider’s stock after acquiring an additional 23,985 shares during the period. Daymark Wealth Partners LLC’s holdings in STERIS were worth $7,330,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC bought a new position in shares of STERIS during the 4th quarter valued at about $414,000. Sei Investments Co. increased its position in STERIS by 1.2% in the fourth quarter. Sei Investments Co. now owns 151,677 shares of the medical equipment provider’s stock worth $33,347,000 after purchasing an additional 1,860 shares during the last quarter. Logan Capital Management Inc. raised its stake in STERIS by 31.3% during the fourth quarter. Logan Capital Management Inc. now owns 1,103 shares of the medical equipment provider’s stock valued at $242,000 after purchasing an additional 263 shares in the last quarter. Frontier Capital Management Co. LLC lifted its position in STERIS by 8.0% during the fourth quarter. Frontier Capital Management Co. LLC now owns 264,135 shares of the medical equipment provider’s stock valued at $58,070,000 after purchasing an additional 19,587 shares during the last quarter. Finally, Caden Capital Partners LP raised its position in shares of STERIS by 80.0% during the 4th quarter. Caden Capital Partners LP now owns 82,312 shares of the medical equipment provider’s stock valued at $18,096,000 after buying an additional 36,576 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. JMP Securities restated a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. Stephens reiterated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a report on Wednesday, August 7th. Finally, KeyCorp upped their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $246.00.

Insider Buying and Selling

In other STERIS news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

STERIS Stock Performance

STERIS stock traded up $0.65 during mid-day trading on Wednesday, hitting $227.87. The company had a trading volume of 250,335 shares, compared to its average volume of 468,948. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $22.47 billion, a price-to-earnings ratio of 59.48 and a beta of 0.84. The company’s fifty day moving average is $237.60 and its 200-day moving average is $225.79. STERIS plc has a 12-month low of $195.47 and a 12-month high of $248.24.

STERIS (NYSE:STE) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.16. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same period in the prior year, the company posted $2.00 EPS. The company’s revenue for the quarter was down .4% on a year-over-year basis. Equities research analysts predict that STERIS plc will post 9.06 EPS for the current year.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were given a dividend of $0.57 per share. This is a positive change from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.00%. STERIS’s dividend payout ratio (DPR) is 59.69%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.